Lipid Lowering Drugs in Acute Coronary Syndromes (ACS).

ABSTRACT:

Purpose of review

The purpose of this review is to critically discuss whether more aggressive lipid-lowering strategies are needed in patients with acute coronary syndromes (ACS).

Recent findings

Currently, available data on early (in-hospital/discharge) administration of potent lipid-lowering drugs, such as proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in patients during the vulnerable post-ACS phase, have clearly demonstrated clinical efficacy of the "strike early and strike strong" approach not only for rapid reduction of low-density lipoprotein cholesterol (LDL-C) to unprecedentedly low levels, but also for associated favorable composition of coronary plaque. Intensive lipid-lowering therapy with rapid achievement of the LDL-C treatment goal in ACS patients

SUBMITTER: Arnold N 

PROVIDER: S-EPMC10770191 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature